IPG Photonics Q3 Results Top Estimates; Guides Q4 Revenues Below Estimates - Quick Facts

IPG Photonics Corp. (IPGP) reported Tuesday that net income attributable to IPG for the third quarter more than doubled to $75.4 million or $1.40 per share from $35.6 million or $0.66 per share in the prior-year quarter.

Revenues for the quarter increased 19 percent to $379.2 million from $318.4 million in the same quarter last year, driven by improved demand in Europe and the U.S. as well as growth in emerging products and applications.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.27 per share on revenues of $368.26 million for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to the fourth quarter, the company expects earnings in a range of $1.00 to $1.30 per share on revenues between $330 million and $360 million. The Street is looking for earnings of $1.30 per share on revenues of $366.47 million for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT